| 1 |
34653270 | Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series. | 2022 Feb |
4 |
| 2 |
34774343 | A review of FLT3 inhibitors in acute myeloid leukemia. | 2022 Mar |
1 |
| 3 |
34886738 | Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. | 2022 Feb |
1 |
| 4 |
35198371 | Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy. | 2022 |
1 |
| 5 |
35462331 | ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia. | 2022 Jun |
4 |
| 6 |
35483923 | FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. | 2022 Apr 30 |
1 |
| 7 |
35486475 | Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications. | 2022 Apr 29 |
2 |
| 8 |
35496349 | Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy. | 2022 |
3 |
| 9 |
35532877 | FLT3-targeted treatment for acute myeloid leukemia. | 2022 May 9 |
2 |
| 10 |
35549749 | The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report. | 2022 May |
3 |
| 11 |
35565314 | Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. | 2022 Apr 27 |
1 |
| 12 |
35637252 | Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. | 2022 May 30 |
1 |
| 13 |
32949053 | Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission. | 2021 Jan |
2 |
| 14 |
33025066 | Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. | 2021 Jan |
4 |
| 15 |
33242449 | Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. | 2021 Jan |
1 |
| 16 |
33288862 | Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. | 2021 May |
2 |
| 17 |
33373830 | Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. | 2021 Jan |
1 |
| 18 |
33531064 | Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. | 2021 Feb 2 |
2 |
| 19 |
33598693 | Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. | 2021 Jun 3 |
3 |
| 20 |
33654204 | Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. | 2021 Sep |
2 |
| 21 |
33677444 | Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. | 2021 |
1 |
| 22 |
33879026 | Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study. | 2021 Oct |
1 |
| 23 |
34045454 | FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. | 2021 May 27 |
3 |
| 24 |
34172833 | Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. | 2021 Jun 25 |
3 |
| 25 |
34424108 | Safety of FLT3 inhibitors in patients with acute myeloid leukemia. | 2021 Sep |
1 |
| 26 |
34660293 | Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. | 2021 |
1 |
| 27 |
34889359 | What to use to treat AML: the role of emerging therapies. | 2021 Dec 10 |
1 |
| 28 |
31291613 | Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. | 2020 |
1 |
| 29 |
31471587 | Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. | 2020 Mar |
1 |
| 30 |
31752581 | Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals. | 2020 Apr |
5 |
| 31 |
31782821 | Midostaurin and cyclosporine drug interaction: A case report. | 2020 Apr |
1 |
| 32 |
31919472 | FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. | 2020 Mar |
1 |
| 33 |
31955389 | Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. | 2020 May |
1 |
| 34 |
31967735 | Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. | 2020 Mar |
5 |
| 35 |
31970530 | Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. | 2020 Jun |
4 |
| 36 |
32085993 | A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. | 2020 Apr |
4 |
| 37 |
32109580 | The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. | 2020 May |
1 |
| 38 |
32215183 | Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. | 2020 Mar 17 |
1 |
| 39 |
32297538 | Acute myeloid leukemia transformed to a targetable disease. | 2020 May |
1 |
| 40 |
32418523 | FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects. | 2020 |
1 |
| 41 |
32468606 | Anticancer activity of bisindole alkaloids derived from natural sources and synthetic bisindole hybrids. | 2020 Sep |
1 |
| 42 |
32477567 | Advances in targeted therapy for acute myeloid leukemia. | 2020 |
1 |
| 43 |
32514626 | Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. | 2020 Jul |
1 |
| 44 |
32545904 | Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. | 2020 Jun 14 |
2 |
| 45 |
32567045 | Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. | 2020 Aug |
1 |
| 46 |
32722298 | Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | 2020 Jul 24 |
4 |
| 47 |
32754299 | Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. | 2020 Jul 21 |
5 |
| 48 |
32812818 | Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. | 2020 Dec |
2 |
| 49 |
32825035 | The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. | 2020 Aug 19 |
1 |
| 50 |
32862867 | FLT3 Inhibition in Acute Myeloid Leukemia. | 2020 Sep |
2 |